Auspex Pharmaceuticals appoints Lynn Bleil, Scott Greer to board of directors
Auspex Pharmaceuticals, a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, has announced the expansion of its board of directors with the appointment of two new members: Lynn D. Bleil, former leader of McKinsey & Company's West Coast Healthcare Practice and a leader of the worldwide Healthcare Practice; and R. Scott Greer, managing director of Numenor Ventures, and former founder, chairman and CEO of Abgenix. The total number of Auspex board members is increased to nine.
Bleil retired in Dec. 2013 as a senior partner (director) in the Southern California Office of McKinsey after more than 25 years working exclusively within the healthcare sector. She advised senior management and boards of leading companies across all segments of the healthcare value chain about corporate and business unit strategy, mergers and acquisitions/ integration, marketing and sales, public policy and organization. Most recently, Bleil worked with companies in the biotechnology/specialty pharma and medical device industries, focused on developing corporate strategies, go-to-market/reimbursement strategies and organizational capabilities to address the rapidly changing payor/provider landscape in the U.S. and globally.
Greer is a private investor in and consultant to the life sciences industry with more than 25 years of experience. Greer has made direct investments in more than 20 healthcare, technology, and consumer product companies. He was a founder of Abgenix, a publicly traded biotechnology company focused on developing and commercializing human antibody based therapeutics, serving as its CEO from inception in 1996 through 2002 and as chairman of the board from 2000 until 2006, when the company was acquired by Amgen for approximately $2.2 billion. Greer also was an investor in and chairman of the board of Sirna Therapeutics, a publicly traded biotechnology company that was sold to Merck for $1.1 billion in 2007.
Greer currently is a member of the board of Nektar Therapeutics, a publicly-traded late clinical stage biopharmaceutical company, StemCells, a biopharmaceutical company focused on stem cell therapeutics, and chairman of the board of directors of Ablexis, a private development-stage biotechnology company.